NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

Survivor, thanks for this paper by Dr. Liau and company. It seems like they’ve found a way to separate progression in GBM from pseudo progression. But maybe others can weigh in. It says:

In conclusion, by combining dCK-based PET and MRI modalities, we are able to noninvasively localize and quantify immune responses induced by immunotherapy. The percentage of tumor volume containing an activated lymphocytic infiltrate is positively correlated with survival in animals. ITRI not only allows us to quantify the immune response in CNS tumors using noninvasive means, but also serves to standardize how we quantify this immunity, to potentially serve as a predictive biomarker of survival and antitumor immune response in a reproducible fashion among patient populations. Additional studies in patients are needed to explore the clinical significance of the changes observed with these imaging modalities.